Samsara Vision
Samsara Vision is a medical device company focused on advancing treatments for serious retinal diseases through innovative ophthalmic implant technologies. The company is developing solutions designed to address significant unmet needs in patients with advanced retinal degeneration, where existing therapeutic options are limited.
FLUID AI
FluidAI is a healthcare technology company developing artificial intelligence–driven solutions to improve the management of fluid status in hospitalized patients. The company’s platform is designed to support earlier clinical decision making and reduce complications associated with fluid imbalance, a key driver of morbidity, length of stay, and healthcare costs.
KARDIUM
Kardium is a medical technology company focused on the treatment of atrial fibrillation through advanced cardiac mapping and ablation solutions. The company has developed a differentiated platform designed to improve procedural efficiency, clinical outcomes, and physician workflow in the electrophysiology lab.
Huma Therapeutics
Huma is a global healthcare AI company on a mission to accelerate the adoption of digital solutions in care and research. The company is renowned for its role in major national healthcare projects worldwide as well as collaborating with most large pharma companies
Caresyntax
Caresyntax offers AI-powered software, devices, and clinical services designed to enhance surgical outcomes. With a significant global presence in operating rooms, their technology has been utilized in millions of surgeries and boasts a substantial user base of surgical professionals.
NETTWORK HOLDINGS
Nettwork Holdings is a distribution focused company that supports commercialization efforts across the healthcare ecosystem.
Ansella Therapeutics
Ansella Therapeutics is specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes. The company’s initial focus is on women’s health, specifically in the development of novel vaginal formulations.
VIVANCE Technologies
VIVANCE Technologies is a clinical-stage, medical device company that has developed a disruptive peritoneal dialysis (PD) device based on revolutionary new filtration technology developed in-house.
Enquyst Technologies
Enquyst Technologies is developing the next-generation biopharmaceutical manufacturing platform which aims to redesign the downstream bioprocess equipment to bring unprecedented advantages in cost, time, footprint, and speed to market at commercial scale.
Endeavor Biomedicines
Endeavor’s ENV-101 is a second-generation Hedgehog inhibitor with a highly favorable efficacy and side-effect profile compared to the molecules currently in the market. ENV-101 inhibits target pathway by ~90% at all tested doses.